Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia
A von Stackelberg, F Locatelli, G Zugmaier… - Journal of Clinical …, 2016 - repub.eur.nl
Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on
B-cell lymphoblasts. Weevaluated the safety, pharmacokinetics, recommended dosage, and …
B-cell lymphoblasts. Weevaluated the safety, pharmacokinetics, recommended dosage, and …
The effect of ruboxistaurin on nephropathy in type 2 diabetes
OBJECTIVE—Ruboxistaurin selectively inhibits protein kinase C-β and ameliorates kidney
disease in animal models of diabetes. The purpose of this study was to evaluate the effects …
disease in animal models of diabetes. The purpose of this study was to evaluate the effects …
Melatonin suppression by light in euthymic bipolar and unipolar patients
JI Nurnberger, S Adkins, DK Lahiri… - Archives of general …, 2000 - jamanetwork.com
Background Previous studies have suggested that bipolar patients are supersensitive to
light suppression of melatonin and that this may be a trait marker for genetic vulnerability …
light suppression of melatonin and that this may be a trait marker for genetic vulnerability …
[PDF][PDF] Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
H Kantarjian, P Fenaux, MA Sekeres… - Journal of Clinical …, 2010 - scholar.archive.org
Safety and Efficacy of Romiplostim in Patients With Lower- Risk Myelodysplastic Syndrome
and Thrombocytopenia Page 1 Safety and Efficacy of Romiplostim in Patients With LowerRisk …
and Thrombocytopenia Page 1 Safety and Efficacy of Romiplostim in Patients With LowerRisk …
Results of a randomized, double‐blind study of romiplostim versus placebo in patients with low/intermediate‐1–risk myelodysplastic syndrome and thrombocytopenia
A Giagounidis, GJ Mufti, P Fenaux, MA Sekeres… - Cancer, 2014 - Wiley Online Library
BACKGROUND Thrombocytopenia in patients with myelodysplastic syndrome (MDS) is
associated with shortened survival and an increased risk of evolution to acute myeloid …
associated with shortened survival and an increased risk of evolution to acute myeloid …
Evidence for a locus on chromosome 1 that influences vulnerability to alcoholism and affective disorder
JI Nurnberger Jr, T Foroud, L Flury… - American Journal of …, 2001 - Am Psychiatric Assoc
OBJECTIVE: Depression (major depression or depressive syndrome) is more prevalent in
alcoholic than in nonalcoholic subjects in families with multiple members with alcoholism …
alcoholic than in nonalcoholic subjects in families with multiple members with alcoholism …
Phase 2 study of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
HM Kantarjian, FJ Giles, PL Greenberg… - Blood, The Journal …, 2010 - ashpublications.org
We evaluated the efficacy and safety of romiplostim, a thrombopoietin mimetic, in patients
with low-or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine …
with low-or intermediate-risk myelodysplastic syndromes (MDS) receiving azacitidine …
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
MA Sekeres, H Kantarjian, P Fenaux, P Becker… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Romiplostim is a peptibody protein that augments thrombopoiesis by
activating the thrombopoietin receptor. METHODS: In this phase 2, multicenter, open‐label …
activating the thrombopoietin receptor. METHODS: In this phase 2, multicenter, open‐label …
A randomized controlled trial of romiplostim in patients with low-or intermediate-risk myelodysplastic syndrome receiving decitabine
PL Greenberg, G Garcia-Manero, M Moore… - Leukemia & …, 2013 - Taylor & Francis
Patients with myelodysplastic syndrome (MDS) receiving hypomethylating agents commonly
develop thrombocytopenia. This double-blind study evaluated the efficacy and safety of …
develop thrombocytopenia. This double-blind study evaluated the efficacy and safety of …
Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx Results of Phase 1 and Phase 2 Studies
ES Morgan, Y Tami, K Hu, M Brambatti… - Basic to Translational …, 2021 - jacc.org
Targeting angiotensinogen (AGT) may provide a novel approach to more optimally inhibit
the renin-angiotensin-aldosterone system pathway. Double-blind, placebo-controlled …
the renin-angiotensin-aldosterone system pathway. Double-blind, placebo-controlled …